What is Bremelanotide (Vyleesi)?

Bremelanotide, sold as Vyleesi, is a synthetic peptide that works directly in the brain to boost sexual desire rather than acting on blood flow or hormones like most other treatments. It was FDA-approved in 2019 for premenopausal women with acquired, generalized HSDD — meaning low desire that developed over time and causes real distress. Unlike a daily pill, it is injected about 45 minutes before anticipated sexual activity on an as-needed basis.

How does Bremelanotide (Vyleesi) work?

Bremelanotide activates melanocortin receptors (particularly MC3R and MC4R) in the brain — areas linked to sexual arousal, motivation, and reward. Think of it as flipping on a 'desire signal' in the brain rather than relaxing blood vessels or adjusting hormone levels. This central mechanism is why it can increase desire even when hormonal levels are normal.

What forms does Bremelanotide (Vyleesi) come in?

Bremelanotide comes as a single-use, prefilled auto-injector pen delivering 1.75 mg subcutaneously (under the skin of the abdomen or thigh). It is not available as an oral supplement or over-the-counter product. Compounded versions of PT-141 are available through some specialty pharmacies but are not FDA-approved for this indication.

Where it comes from:

Originally investigated as a potential tanning agent (it does cause some skin darkening), bremelanotide was accidentally discovered to produce spontaneous erections in male researchers during early trials. This led to two decades of clinical development for sexual dysfunction in both men and women, culminating in FDA approval for HSDD in women in June 2019.

What does Bremelanotide (Vyleesi) help with?

• Low sexual desire (women) / HSDD: Bremelanotide is FDA-approved specifically for this. Clinical trials showed that women using it experienced meaningful improvements in satisfying sexual events and significantly less distress about their low desire compared to placebo. It works by activating brain reward and motivation circuits, not by changing hormone levels.
• Sexual arousal difficulties: Because bremelanotide acts centrally on the brain's desire-and-reward pathways, it can increase both the mental and physical aspects of arousal. Women in trials reported improvements in overall sexual function beyond just desire, including arousal and satisfaction.
• Distress from low libido: One of the two co-primary endpoints in pivotal trials was reduction in distress caused by low sexual desire. Women using bremelanotide reported feeling significantly less bothered or upset by their reduced libido, which is a clinically meaningful outcome on its own.
• Low sexual desire (men, off-label): Early human trials of PT-141 in men showed that it could increase sexual desire and arousal, including in men who did not fully respond to PDE5 inhibitors like Viagra. Though not FDA-approved for men, compounded PT-141 is used off-label in men's health settings.
• Erectile dysfunction (off-label, men): Early phase trials demonstrated that bremelanotide induced erections in men with psychogenic erectile dysfunction and some men with organic ED who were non-responders to sildenafil. The mechanism is central (brain-driven) rather than vascular, making it a different approach than standard ED medications.
• Psychogenic sexual dysfunction: Because bremelanotide targets brain-level desire pathways, it may be especially useful when sexual dysfunction has a significant psychological or motivational component rather than being purely physical or hormonal.

Which foods are rich in Bremelanotide (Vyleesi)?

Bremelanotide is a synthetic peptide — it is not found in any food and cannot be meaningfully replicated through diet. However, supporting the brain's dopamine and reward pathways nutritionally can complement overall sexual health. Foods and nutrients that may support libido and sexual function include zinc-rich foods (oysters, pumpkin seeds, beef), dark chocolate (phenylethylamine and flavonoids), foods rich in L-arginine (nuts, legumes, lean meats), and omega-3 fatty acids (fatty fish, flaxseed) for healthy vascular and neurological function. Limiting alcohol and ultra-processed foods also supports healthy sexual desire by keeping hormonal and neurotransmitter signaling balanced.

What are the side effects of Bremelanotide (Vyleesi)?

• Nausea (affects roughly 40% of users: most commonly within 1 hour of injection)
• Facial flushing or warmth
• Headache
• Temporary increase in blood pressure (average +6 mmHg systolic, peaks at 4 hours, resolves by 12 hours)
• Injection site reactions (bruising, pain, redness)
• Transient skin darkening (hyperpigmentation) with repeated use — especially on face, gums, or breasts
• Fatigue
• Hot flashes or feeling overheated
• Vomiting (less common than nausea)

Good to know:

Bremelanotide has a well-characterized side effect profile from large clinical trials. Nausea is common but usually mild to moderate and manageable. The most clinically significant concern is a temporary blood pressure rise occurring shortly after injection — this is why it is contraindicated in people with existing cardiovascular disease. Most side effects resolve within 12 hours.

How much Bremelanotide (Vyleesi) should you take?

• Recommended daily: 1.75 mg subcutaneous injection (single-use auto-injector pen) administered into the abdomen or thigh
• Best time of day: Inject approximately 45 minutes before anticipated sexual activity — timing is flexible based on when activity is expected
• With or without food: No food requirement, but taking an anti-nausea medication (e.g., ondansetron) before or after injection can reduce nausea significantly. Avoid alcohol close to use.
• Time to effect: 45 minutes to 1 hour after injection; effects on desire may last up to 12 hours
• How long to take it: Use only as needed — not intended for daily use. Limit to no more than one dose every 24 hours. Avoid using more than once within a 24-hour window. Long-term repeated use may increase risk of persistent skin hyperpigmentation. Discuss with a prescribing physician; this is a prescription-only medication.